Demethylating Agent Azacitidine on Prevention of Acute Kidney Injury-chronic Kidney Disease Continuum

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Apr 5, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called azacitidine on patients who have experienced acute kidney injury (AKI), particularly those who have had heart surgery. AKI can lead to long-term kidney problems, so the researchers want to see if azacitidine can help prevent these issues from getting worse. The trial will involve patients who are diagnosed with stage 2 or stage 3 AKI after cardiac surgery. Unfortunately, individuals with chronic kidney disease, severe heart failure, liver cirrhosis, or active infections, among other conditions, won't be able to participate.

Participants in the trial will be randomly assigned to receive either azacitidine or a placebo (a dummy treatment) for one week after their AKI diagnosis. They will receive follow-up care to monitor their kidney function and protein levels in urine over the next several months. The researchers will be looking for specific outcomes, such as a significant decline in kidney function or the development of severe kidney disease. This study aims to improve understanding of how to manage kidney health after surgery, which could ultimately help many patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient with cardiac surgery associated-AKI, stage 2 and stage 3
• Exclusion Criteria:
• • Chronic kidney disease
• • Decompensated heart failure (EF \< 45%)
• • Liver cirrhosis, child B or C
• • Acute infection
• • Acute bleeding
• • Long-term use of immunosuppressant other than azacitidine
• • Patients with active cancer other than acute leukemia or myelodysplastic syndrome
• • Leukopenia, anemia or thrombocytopenia
• • Pregnancy